Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.97 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9673965 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL9673975 | 1.00 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL15740333 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29634446 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL30835558 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL3465120 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL117530 | 0.98 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29421176 | 0.97 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL1004341 | 0.97 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL7194509 | 0.97 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | NEUROSEARCH A/S | 2002-11-14 | — | — | US | claimed |
| WO-2016081369-A2 | ALKALOID COMPOUNDS FOR TREATING DEPRESSION, SUBSTANCE ADDICTIONS, AND INDICATIONS ASSOCIATED WITH CHRONIC INFLAMMATION | SRQ PATENT HOLDINGS, LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| US-6680314-B2 | USEFUL FOR THE TREATMENT OF DISEASES INVOLVING THE CHOLINERGIC SYSTEM OF THE CENTRAL NERVOUS SYSTEM, PAIN, INFLAMMATORY DISEASES, DISEASES CAUSED BY SMOOTH MUSCLE CONTRACTIONS, LEARNING DEFICIT, COGNITION DEFICIT, ATTENTION DEFICIT | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | disclosed |
| EP-0984943-B1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | NEUROSEARCH A/S | 2002-11-14 | — | — | US | disclosed |
| US-6420395-B1 | DISORDERS OR DISEASES INVOLVING THE CHOLINERGIC SYSTEM OF THE CENTRAL NERVOUS SYSTEM, PAIN, INFLAMMATORY DISEASES, DISEASES CAUSED BY SMOOTH MUSCLE CONTRACTIONS AND AS ASSISTANCE IN THE CESSATION OF CHEMICAL SUBSTANCE ABUSE. | NEUROSEARCH A/S (DK) | 2002-07-16 | — | — | US | disclosed |
| US-5138062-A | Tranquilizers | PHILIP MORRIS INCORPORATED | 1992-08-11 | — | — | US | disclosed |
| US-5015741-A | Insecticides, aphidicides, psychological disorders, sedatives or tranquilizers | PHILIP MORRIS INCORPORATED (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0421762-A1 | Novel nicotine analogs and method | Philip Morris Products Inc. (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | CHRNA1, CHRNB1, CHRNA3 | CHRNB2 17/4885CHRNA4 19/4885CHRNA7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.